Navigation Links
Slow-release 'jelly' delivers drugs better
Date:1/28/2013

DURHAM, NC -- Duke University biomedical engineers have developed a new delivery system that overcomes the shortcomings of a promising class of peptide drugs very small proteins for treating diseases such as diabetes and cancer.

There are more than 40 peptide drugs approved for use in humans and more than 650 are being tested in clinical studies. One example is the hormone insulin, a peptide that regulates the metabolism of carbohydrates in the body and is used as a drug to treat diabetes.

Despite their effectiveness, peptide drugs cannot achieve their full potential for a number of reasons. They are rapidly degraded in the blood stream and they are cleared rapidly from the body, which requires multiple, frequent injections. Because of this, peptide concentrations in the blood can rise precipitously just after injection and fall dramatically soon thereafter, causing unwanted side effects for patients.

One popular method to solve this problem involves loading peptide drugs into polymer microspheres that are injected under the skin and slowly degrade to release the peptide drug. Microsphere-release technology has proven useful, but has many issues related to its manufacture and ease of patient use, the researchers said.

"We wanted to know if we could create a system that does what the polymer microspheres do, but gets rid of the microspheres and is more patient-friendly," said Ashutosh Chilkoti, Theo Pilkington professor of biomedical engineering in Duke's Pratt School of Engineering.

The new approach involves making a "fusion protein" that consists of multiple copies of a peptide drug fused to a polymer which is sensitive to body heat. The fusion molecule is a liquid in a syringe but transforms into a "jelly" when injected under the skin. Enzymes in the skin then attack the injected drug depot and liberate copies of the peptide, providing a constant and controllable release of the drug over time.

Miriam Amiram, former Chilkoti graduate student and first author on the paper, dubbed the new delivery system POD, for protease-operated depot.

In the latest experiments, published on-line in the journal Proceedings of the National Academy of Sciences, the researchers fused glucagon-like peptide-1 (GLP-1), a hormone that regulates the release of insulin, with a genetically engineered heat-sensitive polymer to create the POD.

"Remarkably, a single injection of the GLP-1 POD was able to reduce blood glucose levels in mice for up to five days, which is 120 times longer than an injection of the peptide alone," Chilkoti said. "For a patient with type 2 diabetes, it would be much more desirable to inject such a drug once a week or once a month rather than once or twice a day.

"Additionally, this approach avoids the peaks and valleys of drug concentrations that these patients often experience," Chilkoti said.

Unlike peptide-loaded microspheres, PODs are also easy to manufacture, because the peptide drug and the heat-sensitive polymer are all made of amino acids. They can be built as one long stretch of amino acids by engineered bacteria.

"This new delivery system provides the first entirely genetically encoded alternative to peptide drug encapsulation for sustained delivery of peptide drugs," Chilkoti said.


'/>"/>

Contact: Richard Merritt
richard.merritt@duke.edu
919-660-8414
Duke University
Source:Eurekalert

Related biology technology :

1. Jellyfish inspires latest ocean-powered robot
2. CEM President and CEO Delivers Commencement Address at the 2012 University of Texas at Austin Chemistry and Biochemistry Department Graduation
3. Specialty Chemical Forum 2012 Kicks Off in Houston; AkzoNobels Frank Sherman Delivers Keynote Address
4. Novel nanotherapeutic delivers clot-busting drugs directly to obstructed blood vessels
5. New technology delivers sustained release of drugs for up to 6 months
6. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
7. FDAs Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
8. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
9. New drugs show promise for preventing absence seizures in children: UBC research
10. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
11. Researchers reveal why some pain drugs become less effective over time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... ProMIS Neurosciences (“ProMIS” or the “Company”) ... it has identified a fourth in a series of novel potential therapeutic targets ... of Alzheimer’s disease (AD). , “This discovery is an important milestone ...
(Date:5/4/2016)... ... ... Proove Biosciences, Inc. , the commercial and research leader in personalized pain ... partnership is designed to advance research in pain genetics in an effort to bring ... new agreement, researchers at Proove Biosciences are able to collaborate with Luda Diatechnko, MD, ...
(Date:5/4/2016)... ALBANY, New York , May 4, 2016 /PRNewswire/ ... published by Transparency Market Research "Metabolomics Market - Global ... - 2024", the metabolomics market is anticipated to expand ... to reach USD 2,494.8 million by 2024. ... known as metabolites, within cells, biofluids, tissues or organisms. ...
(Date:5/3/2016)... May 3, 2016 ... Drug Discovery, Gene Expression) Lab-on-a-chip (IVD & ... Institutes, Diagnostics Centers), Fabrication Technology (Microarrays, Microfluidics) ... the market is expected to reach USD ... Billion in 2015, growing at a CAGR ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
(Date:3/8/2016)...   Valencell , the leading innovator in ... secured $11M in Series D financing. The investment ... fund being launched by UAE-based financial services company ... TDF Ventures and WSJ Joshua Fund. Valencell plans ... growth and accelerate its pioneering innovation in accurate ...
(Date:3/2/2016)... , March 2, 2016 ... announced the addition of the  "Global Biometrics ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... to grow at a CAGR of around ... ) has announced the addition of ...
Breaking Biology News(10 mins):